Literature DB >> 18443956

Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2.

Juejin Wang1, Youhua Xu, Yinyan Xu, Huayuan Zhu, Rongjian Zhang, Guoxin Zhang, Shengnan Li.   

Abstract

Urocortin (UCN) functions via corticotrophin-releasing factor receptors (CRFRs), CRFR1 & 2. CRFR2 is reported to be a tonic suppressor of vascularization, implying its role in tumor angiogenesis. Here, it was found that UCN inhibited the growth of hepatocellular carcinoma (HCC) and reduced tumor microvessel density in nude mice. Hepatoma cells didn't express CRFRs whereas vessels expressed CRFRs, mainly CRFR2. In vitro three-dimensional culture assay showed UCN inhibited angiogenesis, this effect was abolished by CRFR2 antagonist, anti-sauvagine-30, demonstrating involvement of CRFR2. Furthermore, UCN inhibited the proliferation and promoted the apoptosis of endothelial cells and down-regulated VEGF expression in vivo via CRFR2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443956     DOI: 10.1080/07357900701788106

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  17 in total

1.  TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma.

Authors:  Daniel Wai-Hung Ho; Alan Ka-Lun Kai; Irene Oi-Lin Ng
Journal:  Front Med       Date:  2015-08-14       Impact factor: 4.592

Review 2.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

3.  Corticotropin Releasing Hormone and Urocortin 3 Stimulate Vascular Endothelial Growth Factor Expression through the cAMP/CREB Pathway.

Authors:  Sang Hoon Rhee; Elise L Ma; Yunna Lee; Yvette Taché; Charalabos Pothoulakis; Eunok Im
Journal:  J Biol Chem       Date:  2015-09-08       Impact factor: 5.157

4.  Structural basis for hormone recognition by the Human CRFR2{alpha} G protein-coupled receptor.

Authors:  Kuntal Pal; Kunchithapadam Swaminathan; H Eric Xu; Augen A Pioszak
Journal:  J Biol Chem       Date:  2010-10-21       Impact factor: 5.157

5.  Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors.

Authors:  Youhua Xu; Rongjian Zhang; Jie Chen; Qichun Zhang; Juejin Wang; Jue Hu; Xiaowei Guan; Lai Jin; Hong Fu; Bo Gui; Yuanyuan Guo; Shengnan Li
Journal:  Br J Pharmacol       Date:  2009-06-30       Impact factor: 8.739

6.  An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population.

Authors:  Xing Gu; Peng Qi; Feiguo Zhou; Qiang Ji; Hao Wang; Tonghai Dou; Yunpeng Zhao; Chunfang Gao
Journal:  Hum Genet       Date:  2009-10-08       Impact factor: 4.132

7.  Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-beta 1 and VEGF.

Authors:  Xuan Li; Jue Hu; Qichun Zhang; Xiaoyu Sun; Shengnan Li
Journal:  Br J Pharmacol       Date:  2009-05-18       Impact factor: 8.739

8.  Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells.

Authors:  Rihong Cong; Qingmin Sun; Li Yang; Haijuan Gu; Ying Zeng; Bin Wang
Journal:  J Exp Clin Cancer Res       Date:  2009-09-07

9.  Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation.

Authors:  Hossein Tezval; Stefanie Jurk; Farahnaz Atschekzei; Jan U Becker; Olaf Jahn; Jürgen Serth; Markus A Kuczyk
Journal:  World J Urol       Date:  2009-12       Impact factor: 4.226

10.  The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress.

Authors:  Alicia Arranz; Maria Venihaki; Berber Mol; Ariadne Androulidaki; Erini Dermitzaki; Olga Rassouli; Jorge Ripoll; Efstathios N Stathopoulos; Rosa P Gomariz; Andrew N Margioris; Christos Tsatsanis
Journal:  Mol Cancer       Date:  2010-09-27       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.